About Modulim
Modulim is a company based in Irvine (United States) founded in 2002 by David Cuccia. Modulim has raised $12.36 million across 16 funding rounds from investors including NIH, Fresenius Medical Care and HHS. Modulim offers products and services including Imaging Solutions and Data Solutions. Modulim operates in a competitive market with competitors including Mimosa Diagnostics, OxiLight, O’Brien Medical, Medical Monofilament and Innovative Wellness Systems, among others.
- Headquarter Irvine, United States
- Founders David Cuccia
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Modulated Imaging Inc.
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$12.36 M (USD)
in 16 rounds
-
Latest Funding Round
$7 M (USD), Series B
Dec 20, 2018
-
Investors
NIH
& 9 more
-
Employee Count
Not available
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Modulim
Modulim offers a comprehensive portfolio of products and services, including Imaging Solutions and Data Solutions.
Provides tools for assessing lower limb health through microvascular data.
Offers insights to manage complications from diabetes and related diseases.
People of Modulim
Unlock access to complete
Electrical Team
1 people
Leadership Team
1 people
Founder Team
1 people
Software Development Team
1 people
Unlock access to complete
Funding Insights of Modulim
Modulim has successfully raised a total of $12.36M across 16 strategic funding rounds. The most recent funding activity was a Series B round of $7 million completed in December 2018. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Modulim
Modulim has secured backing from 10 investors, including venture fund and institutional investors. Prominent investors backing the company include NIH, Fresenius Medical Care and HHS.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Investment in hard tech for planetary health, focusing on materials science, chemistry, and biology.
|
Locked | Locked | Locked | |
|
-
|
Locked | Locked | Locked | |
|
Venture capital is invested in AI, energy, and various sectors.
|
Locked | Locked | Locked |
Investor details for Modulim
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Modulim
Investment portfolio details for Modulim
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Modulim
Detailed financials for Modulim
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Modulim Comparisons
Peer comparison for Modulim
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Modulim
Modulim operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Mimosa Diagnostics, OxiLight, O’Brien Medical, Medical Monofilament and Innovative Wellness Systems, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Early foot ulcer detection is facilitated by non-invasive mHealth technology.
|
|
| Locked | Locked | Locked |
Wound imaging solutions for diabetic foot ulcers and peripheral vascular disease
|
|
| Locked | Locked | Locked |
Medical devices for neuropathy diagnosis and monitoring are developed.
|
|
| Locked | Locked | Locked |
Manufactures sensory testing monofilaments to aid diabetic foot care and prevention.
|
|
| Locked | Locked | Locked |
Produces high-quality biomechanical footwear for diabetic foot ulcer care and analysis.
|
Detailed competitors of Modulim
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Modulim
Complete news archive for Modulim
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Modulim
Modulim was founded in 2002 and raised its 1st funding round 4 years after it was founded.
Modulim is headquartered in Irvine, United States. It is registered at Irvine, California, United States.
Amaan Mazhar is the current CEO of Modulim.
Modulim is a funded company, having raised a total of $12.36M across 16 funding rounds to date.
Modulim provides the non-invasive imaging devices for detection of diabetic foot ulcer. It measuring microvascular tissue oxygenation and hemoglobin concentration by Spatial Frequency Domain Imaging technique for detection. Its flagship product is Clarifi which is non-contact device that measures critical hemoglobin biomarkers in tissue.
Modulim's top competitors include Mimosa Diagnostics, O’Brien Medical and OxiLight.
Modulim offers Imaging Solutions and Data Solutions.
Modulim has 10 investors. Key investors include NIH, Fresenius Medical Care, HHS, Hamamatsu Photonics, and Pangaea Ventures.